Newly FDA Approved Cancer Treatment Comes to Bel Air

August 27, 2015

BEL AIR, M.D. – Aug. 27, 2015 – A newly FDA approved treatment for advanced prostate cancer is now available in Harford County. Xofigo®, a radiopharmaceutical given intravenously for late stage prostate cancer, will now be offered at 21st Century Oncology of Maryland (Chesapeake Radiation Oncology).

Xofigo has been shown to increase survival rates and delay complications in patients with advanced stage prostate cancer that has metastasized to bone. Xofigo received FDA approval within the last two years after extensive research showed patients lived an average of 3.6 months longer with the treatment than without.

According to the National Cancer Institute, over 220,000 men will be diagnosed with prostate cancer and over 27,000 will die from the disease in 2015. Treatment options for men whose cancer has metastasized to bone after receiving medical or surgical therapy have been limited.

21st Century Oncology of Maryland administers Xofigo in a convenient outpatient setting.

“We are pleased to offer this state-of-the-art, life-prolonging cancer therapy to men with advanced stage prostate cancer,” says Board Certified Radiation Oncologist Vladimir Ioffe, M.D. “Xofigo® has the potential to help reduce pain and increase survival in patients with advanced stage prostate cancer. We are proud to offer this treatment to men in our community.”

21st Century Oncology of Maryland (Chesapeake Radiation Oncology) is located at 602 South Atwood Road, Suite 105, Bel Air, MD 21014.

For more information about our services, visit or call (410) 836-0354.

About 21st Century Oncology:

21st Century Oncology is the largest global, physician led provider of Integrated Cancer Care services. The company offers a comprehensive range of cancer treatment services, focused on delivering academic quality, cost-effective patient care in personal and convenient settings. As of June 30, 2015, the company operated 183 treatment centers, including 148 centers located in 17 states and 35 centers located in six countries in Latin America. The company holds market-leading positions in most of its domestic local markets and abroad.


To top